Shattuck Labs SL-9258 /Anti-PD(L)1 Shows Broadened Anti-Tumor Activity In CPI-Resistant Cancers
Shattuck Labs Inc (NASDAQ:STTK) announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting, including data from…
Shattuck Labs To Present Preclinical Data At AACR
- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors -
- Butyrophilin heterodimeric fusion proteins from
Needham Maintains Buy on Shattuck Labs, Lowers Price Target to $31
Needham analyst Gil Blum maintains Shattuck Labs (NASDAQ:STTK) with a Buy and lowers the price target from $46 to $31.
Shattuck Labs Q4 EPS $(0.18) Up From $(0.31) YoY, Sales $30.10M Up From $1.34M YoY
Shattuck Labs (NASDAQ:STTK) reported quarterly losses of $(0.18) per share. This is a 41.94 percent increase over losses of $(0.31) per share from the same period last year. The company reported $30.10 million in sales
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 109 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows.
